Our team
WiTT's team is made up of healthcare and technology experts passionate about driving positive change across the continuum of healthcare.
Our advisory board
"I am humbled and honored to have the opportunity to work with such a great group of incredible people who see the potential in what we are building. I am excited to leverage their expertise, connections, and insight to enable us to accelerate our vision of removing the non-clinical barriers cancer patients face as they go through treatment."
– Rahul Mahadevan, Founder and CEO of the WiTT Group, Inc.
Adam is the Founder and Principal of Vertex Health, where he works to help companies succeed in building, using, and deploying healthcare technology. He has over 20 years of experience as a physician and healthcare IT executive with demonstrated success in leading large-scale change within and across organizations, ranging fromn early-stage startup to big tech enterprise. At Vertex Health, Adam has a wide-reaching client portfolio serving as a Senior Advisor to ARPA-H, Strategic Advisor to American Cancer Society BrightEdge, and in various capacities with multiple high-potential healthtech startups.
Prior to starting Vertex Health, Adam was the Global Head of Healthcare for Public Sector Venture Capital and Startups at Amazon Web Services (AWS). In this role, he led a team of healthtech deep subject matter experts focused on fostering startup communities and driving the adoption of startups with healthcare customers around the world. Before joining Amazon, Adam was Chief Innovation Officer and Associate Chief Medical Information Officer at Virtua Health, where he founded both Virtua’s telehealth program and Center for Innovation. In these roles, he worked closely with clinical leadership, operational leadership, and government agencies to transform clinical workflows through the seamless integration of technology.
A pediatric hospitalist by training, Adam practiced clinical medicine for 15 years working as part of the Children’s Hospital of Philadelphia at Virtua group in a pediatric emergency department. He is board certified in both Pediatrics and Clinical Informatics, and has a Master’s Degree of Science in Health Informatics. This cumulative experience in the clinical, technical, and business worlds has led Adam to where he is today, as he seeks to effect the largest change possible to improve healthcare for all those along the care delivery spectrum.
Deepak is an experienced Board Member and Medical Device Executive with a demonstrated history of working in the hospital & health care industry. He is the current SVP & Chief Medical Officer at Varian Medical Systems, a Siemens Healthineers company, and is a practicing oncologist. His Residency was focused in Radiation Oncology from Cleveland Clinic Foundation.
There are many reasons why I am so honored to be part of the advisory team, but the most important to me is that WiTT has the ability to help patients going through treatment address some of the day-to-day burdens that could prevent patients from making their appointments. In many cases, its critical for cancer patients to make it to their appointments when scheduled; if not, this could adversely impact our ability to cure a cancer. WiTT has the ability to impact outcomes as much as therapy itself!
Kolleen has extensive experience in global healthcare and medical technology markets with areas of expertise that include strategy development, portfolio innovation, multi-billion dollar P&L management as well as corporate governance and stewardship. She retired from Varian Medical Systems in December 2021 after 24 years, holding numerous executive roles including President of Oncology Systems, Proton Solutions and Chief Growth Officer. She currently sits on a variety of non-profit and for-profit boards.
I am incredibly excited by the vision of WiTT to enable patients in need to successfully overcome the multitude of obstacles faced in traversing their healthcare journey. The support provided by WiTT is a catalyst for improved treatment compliance, extending caregiver capacity and bringing hope to those patients who might not otherwise have access or the resources to obtain care.
Lori was the Vice President of Patient Advocacy and Diversity in Clinical Research at WCG. In her last corporate role, Lori was the Director of Diversity & Patient Engagement in R&D at Bristol-Myers Squibb (BMS). She built one of the first R&D diversity & clinical trial advocacy groups in pharma and focused on bringing awareness, accessibility, and the voice of the patient to clinical trials across multiple therapeutic areas. Moreover, her team concentrated on health disparities, and identified strategies for building relationships in minority communities. Her work has been recognized by Pharma Voice 100.I have spent the better part of my career seeking solutions to build health equity in clinical trials. While building awareness and accessibility to clinical trials is essential, equally important is providing the day-to-day help that people need to free them up to participate. Missing a few days of work during the month may not be prohibitive to participating in a clinical trial, if someone else can assist paying the rent, or babysitting, or buying food for the week. Unfortunately, in the real world there are additional pressures beyond being sick. I believe WiTT will relieve some of these concerns and thereby increase adherence in clinical trials.
Matt spent over 20 years as the Senior Managing Director and Chief Venture Investment Officer at Ascension Ventures where his team was responsible for deploying $1+ billion in capital across 5 funds from 19 not-for-profit health system partners with a unique engagement / governance model. He turned Ascension Ventures from an idea into an industry leading platform and continues to advise entrepreneurs and companies trying to fix healthcare's big problems.
For too long we have been talking about putting the patient in the center of their healthcare. WiTT is the first company I have come across that is actually doing that by helping solve patient's non-clinical needs in a unique way. I am excited to be part of their advisory team and leverage my network to help them address a critical gap in care that I believe will help health systems, health plans, and most importantly, patients.
As chief medical officer, Dr. Zafar leads AccessHope’s clinical infrastructure. He is a practicing oncologist with over 20 years of clinical and research experience. Dr. Zafar has over 130 peer-reviewed publications in high- impact journals. His internationally recognized research was funded by the National Cancer Institute and the American Cancer Society, among others. His work has been covered by the New York Times, Forbes, Wall Street Journal, NPR, and Washington Post.
Previously, he has served as senior vice president for medical informatics at Optum Insight. Prior to Optum, Dr. Zafar was a professor of medicine and the chief quality & innovation officer at the Duke Cancer Institute. At Duke he built multiple solutions to optimize cancer care quality, including an oncology acute care clinic, an AI-driven model to improve end-of-life care, and an early-access clinic for newly diagnosed patients.
Dr. Zafar completed his internal medicine residency at the University of Cincinnati Medical Center and his medical oncology fellowship at the Duke University Medical Center. He earned a master’s degree in clinical research at Duke. He is board-certified in medical oncology. He is a Fellow of the American Society of Clinical Oncology and an adjunct professor at Duke University School of Medicine.